Astria Therapeutics Inc (ATXS)

Mar 12, 2025

Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView

Mar 12, 2025

Mar 12, 2025

Astria Therapeutics price target raised to $28 from $27 at Wedbush - TipRanks

Mar 12, 2025

Mar 12, 2025

Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World

Mar 12, 2025

Mar 12, 2025

Astria Therapeutics Advances Clinical Trials and Financials - TipRanks

Mar 12, 2025

Mar 11, 2025

Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating - TipRanks

Mar 11, 2025

Mar 11, 2025

Astria Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 11, 2025

Mar 11, 2025

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - BioSpace

Mar 11, 2025

Mar 11, 2025

Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating - TipRanks

Mar 11, 2025

Mar 11, 2025

Astria Therapeutics posts marginally smaller-than-expected quarterly net loss per share - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView

Mar 11, 2025

Mar 07, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by New York State Common Retirement Fund - Defense World

Mar 07, 2025

Mar 07, 2025

Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.67 - Defense World

Mar 07, 2025

Mar 04, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com

Mar 04, 2025

Mar 04, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 04, 2025

Mar 03, 2025

Learn to Evaluate (ATXS) using the Charts - Stock Traders Daily

Mar 03, 2025

Mar 02, 2025

Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 02, 2025

Mar 01, 2025

Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World

Mar 01, 2025

Feb 28, 2025

HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat

Feb 28, 2025

Feb 27, 2025

Astria Therapeutics (ATXS) Expected to Announce Quarterly Earnings on Monday - MarketBeat

Feb 27, 2025

Feb 27, 2025

Press Release From Business Wire: Astria Therapeutics, Inc. - UrduPoint News

Feb 27, 2025

Feb 27, 2025

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema - Business Wire

Feb 27, 2025

Feb 27, 2025

Can Astria's Navenibart Change the Game for HAE Patients? Phase 3 Trial Begins After 95% Attack Reduction - StockTitan

Feb 27, 2025

Feb 25, 2025

Can Astria Therapeutics' Conference Appearance Signal New Developments in Allergic Disease Treatments? - StockTitan

Feb 25, 2025

Feb 25, 2025

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference - Business Wire

Feb 25, 2025

Feb 22, 2025

Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance

Feb 22, 2025

Feb 21, 2025

When the Price of (ATXS) Talks, People Listen - Stock Traders Daily

Feb 21, 2025

Feb 20, 2025

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business Wire

Feb 20, 2025

Feb 18, 2025

Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average – What’s Next? - Defense World

Feb 18, 2025

Feb 17, 2025

Astria Therapeutics: A High-Conviction Bet On HAE - Seeking Alpha

Feb 17, 2025

Feb 12, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Price Target from Analysts - Defense World

Feb 12, 2025

Feb 10, 2025

How to Take Advantage of moves in (ATXS) - Stock Traders Daily

Feb 10, 2025

Feb 10, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Target Price from Brokerages - MarketBeat

Feb 10, 2025

Feb 04, 2025

Astria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Citizens Jmp - MarketBeat

Feb 04, 2025

Feb 04, 2025

Astria Therapeutics (NASDAQ:ATXS) Now Covered by Analysts at JMP Securities - MarketBeat

Feb 04, 2025

Feb 04, 2025

Angioedema Pipeline 2024: Therapies Under Investigation, - openPR

Feb 04, 2025

Feb 04, 2025

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - sharewise

Feb 04, 2025

Feb 04, 2025

Astria wins new Outperform rating at JMP on drug technology - MSN

Feb 04, 2025

Feb 03, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - MarketBeat

Feb 03, 2025

Feb 03, 2025

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session - Business Wire

Feb 03, 2025

Feb 03, 2025

Breakthrough HAE Treatment Data: Navenibart Shows Rapid Quality of Life Improvements in Clinical Trial - StockTitan

Feb 03, 2025

Feb 01, 2025

JMP Securities starts Astria Therapeutics stock at Market Outperform - MSN

Feb 01, 2025

Feb 01, 2025

JMP Securities Initiates Coverage of Astria Therapeutics (ATXS) with Market Outperform Recommendation - MSN

Feb 01, 2025

Jan 31, 2025

Astria Therapeutics' Shares Rise After JMP Securities Initiates Coverage With Outperform Rating - Marketscreener.com

Jan 31, 2025

Jan 31, 2025

Astria stock wins new Outperform at JMP (ATXS:NASDAQ) - Seeking Alpha

Jan 31, 2025

Jan 31, 2025

JMP Securities starts Astria Therapeutics stock at Market Outperform By Investing.com - Investing.com Canada

Jan 31, 2025

Jan 31, 2025

JMP Securities Initiates Astria Therapeutics at Outperform -January 31, 2025 at 08:17 am EST - Marketscreener.com

Jan 31, 2025

Jan 31, 2025

JMP Securities starts Astria Therapeutics stock with $26 target By Investing.com - Investing.com Canada

Jan 31, 2025

Jan 29, 2025

JPMorgan Chase & Co. Increases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Jan 29, 2025